Keyphrases
Peru
100%
Cost-effectiveness
88%
Pneumonia
35%
Peruvian
33%
Treatment Impact
28%
Treatment Adherence
28%
Multiple Sclerosis
28%
Interferon Therapy
28%
Patient Support
28%
7-valent
28%
Cost-effectiveness Analysis
28%
13-valent
28%
Pneumococcal Conjugate Vaccine
28%
13-valent Pneumococcal Conjugate Vaccine (PCV13)
28%
Entecavir
28%
Tenofovir
28%
Chronic Hepatitis B
28%
Antiretroviral Therapy
28%
Interferon-α (IFN-α)
24%
PCV7
24%
PCV10
24%
GDP per Capita
17%
Quality-adjusted Life Years
15%
Cetuximab
14%
Metastatic Colorectal Cancer (mCRC)
14%
Chemotherapy
14%
Patterns of Care
14%
Ischemic Heart Disease
14%
Treatment Strategy
14%
Chemotherapy Alone
14%
Carbapenem-resistant Bacteria
14%
Ceftazidime-avibactam
14%
Hospitalization
12%
Incremental Cost-effectiveness Ratio
11%
Public Hospitals
11%
Willingness to Pay
11%
High Cost
10%
Health Care Costs
10%
Sensitivity Analysis
9%
Markov Model
9%
Ministry of Health
9%
Colistin
8%
Streptococcus Pneumoniae
8%
5-year-old
8%
Tornado Analysis
7%
Bacteremia
7%
Carbapenem-resistant Enterobacteria
7%
Economic Model
6%
Effectiveness Ratio
5%
Discount Rate
5%
Treatment Costs
5%
Hepatitis B Treatment
5%
Direct Costs
5%
Model Uncertainty
5%
Hepatitis B Virus
5%
Net Profit
5%
Cost Ratio
5%
Health Status
5%
Pharmacology, Toxicology and Pharmaceutical Science
Interferon
28%
Multiple Sclerosis
28%
Chronic Hepatitis B
28%
Antiviral Therapy
28%
Tenofovir
28%
Entecavir
28%
Infection
14%
Chemotherapy
14%
Metastatic Colon Cancer
14%
Cetuximab
14%
Carbapenem
14%
Avibactam Plus Ceftazidime
14%
Pneumococcus Vaccine
14%
Streptococcus Pneumonia
9%
Colistimethate
8%
Enterobacteriaceae
7%
Bloodstream Infection
7%
Hepatitis B Virus
5%
Health Status
5%
Nursing and Health Professions
Cost Effectiveness Analysis
42%
Interferon
28%
Multiple Sclerosis
28%
Patient Compliance
28%
Ischemic Heart Disease
14%
Cetuximab
14%
Metastatic Colon Cancer
14%
Quality Adjusted Life Year
9%
Disease
5%